Purpose: Procalcitonin (PCT) may be an effective biomarker in the management of lower respiratory tract infections (LRTI) when combined with antimicrobial stewardship support. We assessed the impact of a PCT protocol with clinical pharmacy support for LRTI using a clinical decision support system (CDSS) for monitoring. Methods: This was a single-center retrospective cohort study conducted at a large, nonteaching hospital in Nashville, TN. All patients who met eligibility requirements and were initiated on the PCT protocol for a suspected LRTI between February and March 2018 were included and matched to historical control patients from 2016 to 2017 on a 1:1 basis based on antibiotics, indication, and time of year. Results: During this 2-month period, a total of 126 patients met eligibility requirements for inclusion in the PCT group and were matched to historical control patients. Patients in the PCT group received decreased median antibiotic days of therapy (DOT) compared to controls (11 vs 14, P = .004). There was no change in median length of stay (LOS) between groups. The acceptance rate for patient-specific antibiotic de-escalation recommendations from the clinical pharmacist was 62.5%. Conclusion: PCT protocols that utilize clinical pharmacist interpretation and a CDSS may be an effective intervention of the antimicrobial stewardship program (ASP) for decreasing antibiotic DOT for LRTI.
Purpose: Procalcitonin (PCT) may be an effective biomarker in the management of lower respiratory tract infections (LRTI) when combined with antimicrobial stewardship support. We assessed the impact of a PCT protocol with clinical pharmacy support for LRTI using a clinical decision support system (CDSS) for monitoring. Methods: This was a single-center retrospective cohort study conducted at a large, nonteaching hospital in Nashville, TN. All patients who met eligibility requirements and were initiated on the PCT protocol for a suspected LRTI between February and March 2018 were included and matched to historical control patients from 2016 to 2017 on a 1:1 basis based on antibiotics, indication, and time of year. Results: During this 2-month period, a total of 126 patients met eligibility requirements for inclusion in the PCT group and were matched to historical control patients. Patients in the PCT group received decreased median antibiotic days of therapy (DOT) compared to controls (11 vs 14, P = .004). There was no change in median length of stay (LOS) between groups. The acceptance rate for patient-specific antibiotic de-escalation recommendations from the clinical pharmacist was 62.5%. Conclusion: PCT protocols that utilize clinical pharmacist interpretation and a CDSS may be an effective intervention of the antimicrobial stewardship program (ASP) for decreasing antibiotic DOT for LRTI.
Authors: Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi Journal: Clin Infect Dis Date: 2016-04-13 Impact factor: 9.079
Authors: Sarah H Yi; Kelly M Hatfield; James Baggs; Lauri A Hicks; Arjun Srinivasan; Sujan Reddy; John A Jernigan Journal: Clin Infect Dis Date: 2018-04-17 Impact factor: 9.079
Authors: Philipp Schuetz; Yannick Wirz; Ramon Sager; Mirjam Christ-Crain; Daiana Stolz; Michael Tamm; Lila Bouadma; Charles E Luyt; Michel Wolff; Jean Chastre; Florence Tubach; Kristina B Kristoffersen; Olaf Burkhardt; Tobias Welte; Stefan Schroeder; Vandack Nobre; Long Wei; Heiner C Bucher; Djillali Annane; Konrad Reinhart; Ann R Falsey; Angela Branche; Pierre Damas; Maarten Nijsten; Dylan W de Lange; Rodrigo O Deliberato; Carolina F Oliveira; Vera Maravić-Stojković; Alessia Verduri; Bianca Beghé; Bin Cao; Yahya Shehabi; Jens-Ulrik S Jensen; Caspar Corti; Jos A H van Oers; Albertus Beishuizen; Armand R J Girbes; Evelien de Jong; Matthias Briel; Beat Mueller Journal: Lancet Infect Dis Date: 2017-10-13 Impact factor: 25.071
Authors: Wesley H Self; Robert A Balk; Carlos G Grijalva; Derek J Williams; Yuwei Zhu; Evan J Anderson; Grant W Waterer; D Mark Courtney; Anna M Bramley; Christopher Trabue; Sherene Fakhran; Anne J Blaschke; Seema Jain; Kathryn M Edwards; Richard G Wunderink Journal: Clin Infect Dis Date: 2017-07-15 Impact factor: 9.079
Authors: Jennifer Townsend; Victoria Adams; Panagis Galiatsatos; David Pearse; Hardin Pantle; Mary Masterson; Flora Kisuule; Elsen Jacob; Catherine Kiruthi; Paul Ortiz; Albert Agbanlog; Robert Jurao; Sam Stern; Seema Nayak; Michael Melgar; Jacob Sama; Jillian Irwin; Cyrus Mazidi; Kevin Psoter; Robin McKenzie Journal: Open Forum Infect Dis Date: 2018-12-03 Impact factor: 3.835
Authors: Joshua P Metlay; Grant W Waterer; Ann C Long; Antonio Anzueto; Jan Brozek; Kristina Crothers; Laura A Cooley; Nathan C Dean; Michael J Fine; Scott A Flanders; Marie R Griffin; Mark L Metersky; Daniel M Musher; Marcos I Restrepo; Cynthia G Whitney Journal: Am J Respir Crit Care Med Date: 2019-10-01 Impact factor: 21.405